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Prevention of non-communicable disease: best 
buys, wasted buys, and contestable buys
Wanrudee Isaranuwatchai and colleagues highlight the importance of local context in making 
decisions about implementing interventions for preventing non-communicable diseases
I
ncreasing incidence of non-commu-
nicable diseases (NCDs) creates epi-
demiological and economic burdens 
everywhere and inluences everyone 
regardless of sex and age.1 2 Four main 
NCDs (cardiovascular diseases, diabetes, 
cancer, and chronic respiratory disease) 
account for over 12 million premature deaths 
worldwide annually.3 Mental ill health also 
imposes substantial economic burdens1 and 
should be included in policies for reducing 
the health and inancial burdens of NCDs.
N C D  p o l i c i e s  h ave  s u b s t a n t i a l 
implications for population health and 
national budgets. Countries therefore 
need to assess both the health and the 
inancial aspects of these policies before 
implementation, especially in the context 
of the aim to achieve universal health 
coverage. We consider how to distinguish 
local best buys, wasted buys, and 
contestable buys among evidence based 
NCD interventions to improve setting of 
health priorities and ofer suggestions for 
better decision making processes.
Universal health coverage and prioritisation
Achieving universal health coverage 
requires clear thinking on the difficult 
choices about who is to be covered and 
for what interventions. The World Health 
Organization created a list of “best buys” to 
describe health interventions that are glob-
ally recommended for controlling NCDs.3 4 
They were selected using the following cri-
teria: a demonstrated and quantiied efect, 
cost efectiveness (≤$100 (£80; €90) per 
disability adjusted life year (DALY) averted 
in low and middle income countries), and 
implementability. A recent survey, however, 
found underuse of the best buy interven-
tions, especially in low and middle income 
countries, and noted that insuicient action 
was being taken to reach the goal of reduc-
ing premature mortality from NCDs by a 
third by 2030 set out in the sustainable 
development goals.5 6
One reason for this may be that much of 
the evidence on best buys does not come 
from low or middle income countries,5 
and it is uncertain whether such global 
guidelines are helpful when setting 
priorities in these countries. Concerns exist 
about the transferability of study indings 
mostly from high income countries to other 
countries with diferent disease proiles, 
population characteristics, economic 
structures, health systems platforms, and 
other distinctive local characteristics. 
Moreover, no guideline exists on how to 
implement international research indings 
in these various settings, with varying 
implementation capacities.4
WHO and the Organisation for Economic 
Cooperation and Development have 
estimated that a fifth of total health 
spending in countries is wasted.7 8 The 
waste exists for a multitude of reasons 
ranging from the lack of evidence 
needed to articulate better policy choices 
to governance related issues such as 
fraud and corruption. The waste is far 
more serious in low and middle income 
countries, where the overall disease 
burden is much higher but relatively small 
expenditures can have enormous impact if 
spent wisely. To improve priority setting at 
local level we distinguish best buys, wasted 
buys, and contestable buys recognising the 
importance of context.
How context affects best buys
The cost effectiveness plane is a visu-
alisation of the differences in costs and 
outcomes of policy options, with costs 
plotted on the vertical y axis and efects 
(health gain) on the horizontal x axis (ig 
1). An intervention that delivers no or little 
beneit or that might have adverse efects, 
and that uses up more resources than the 
current scenario is a wasted buy. An inter-
vention is a contestable buy if it has no 
direct evidence of cost efectiveness in the 
country in which the intervention is being 
considered.
The principal criterion for both best 
buys and wasted buys is cost efectiveness. 
Although the methodological principles for 
cost efectiveness analysis are intended to 
be universal, their quantitative application 
often depends on local circumstances 
(context specificity).9 The threshold 
to separate the cost effective from the 
cost ineffective depends on how much 
a decision maker is willing to pay for 
additional health beneit and will therefore 
vary according to economic factors such as 
the budget for public expenditure.
A best buy in one setting could be a 
contestable or wasted buy in another 
setting. For example, although a ixed dose 
combination of antihypertensive and lipid 
lowering drugs was found to be the best buy 
for primary prevention of cardiovascular 
diseases among moderate risk population 
in high income countries,10 11 Tanzania’s 
threshold ($610 per DALY at the time 
of study) was insufficient to warrant 
proceeding and the combination drug 
is a wasted buy in this middle income 
country.12 Evidence on diabetic screening 
in Indonesia and Thailand shows that 
screening is a best buy only for high risk 
groups aged ≥40 rather than from age 15, 
which had been the standard practice.13 14 
Screening people aged 15-39 age was a 
wasted buy, and the savings from focusing 
on the high risk groups released resources 
for other priorities.
Local context can also influence cost 
effectiveness.15 16 For instance, tobacco 
taxation is widely considered to be a 
best buy and is included in WHO’s list.4 
However, in India, the tax on cigarette 
products failed to substantially reduce 
KEY MESSAGES
•   WHO’s list of best buy interventions 
aims to assist the global community’s 
ight on non-communicable diseases
•   Best buys evaluated in one setting 
may not be cost efective in other set-
tings
•   Evaluation of context is essential to 
ensure resources are best deployed 
towards universal health coverage
•   National or international hubs could 
help with this evaluation and build 
evidence to get cross sectoral support 
towards preventing non-communica-
ble disease
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tobacco use even though there was 
international evidence and strong political 
support for implementation. This was 
partly because 85% of smokers in India 
smoked bidi, a local tobacco that was 
not taxed.17 18 Analysis of case studies of 
implementing NCD preventive policies 
in low and middle income countries19 20 
highlights important contextual economic 
and other considerations, including 
relevance to the community of interest; 
ethical acceptability; possibility of 
cross-sectoral collaboration; degree of 
community and stakeholder engagement; 
afordability, feasibility, and sustainability; 
and leadership, governance, compliance, 
and monitoring.15
Beyond cost effectiveness
Clearly, what is best or wasted is more 
than just a question of efectiveness and 
cost. There are other ethical, cultural, 
political, and practical factors, some of 
which are modiiable. In some societies, 
religious taboos or conventions may have 
to be considered. In most, there will be 
concerns for greater health equality and 
reduced exposure to financial risk to 
supplement the eiciency criterion. The 
capacities of countries to use and imple-
ment research on cost efectiveness are 
also varied, which can easily result in mis-
taken judgments even about efectiveness 
and cost. Furthermore, interventions that 
afect NCDs often lie outside the health 
sector, including in education, transporta-
tion, or lifestyle. For example, though not 
in WHO’s best buy list, reducing physical 
inactivity through urban design is a pillar 
of NCD prevention. Bike sharing schemes 
have been advocated globally for many 
reasons related to health, economy, and 
the environment. In some countries, how-
ever, women are not fully able to use the 
schemes for cultural and religious reasons. 
Consequently, something initially lauded 
as a best buy becomes a contestable buy 
because of ambiguity about the interven-
tion itself, the possible inequity it gener-
ates, and its gender bias. The resulting 
gender inequity in these contexts means 
that this intervention is not a best buy for 
the whole population and would need to 
be complemented with a policy to equally 
increase the physical activity of women.
NCD programmes need to balance 
national spending priorities fairly 
and efficiently against one another, 
safeguarding rights to health while having 
due regard for rights to education, security, 
decent housing, and so on. This decision 
requires high level priority setting at which 
budgets for health are determined. Even 
within the health sector, simple criteria 
may not suice. For instance, seeking only 
to maximise health beneits can conlict 
with equity.21 Achieving equity tends to 
become costlier as policy reaches out to less 
accessible, marginalised groups. Exclusion 
of hard-to-reach populations raises 
important ethical questions regarding a just 
distribution of access to healthcare and of 
health itself.
Interventions that are not cost efective 
in one context might still be best buys 
in another. If this is suspected, they are 
“contestable” and may warrant more 
specific local study. Interventions that 
are in principle not cost effective might 
be best buys if they have other attractive 
attributes. For example, in settings with a 
commercial alcohol market rather than a 
tradition of home brewing, implementing 
a minimum unit price for alcohol could 
have more effect on health inequalities 
than simply raising alcohol taxes.22 A cost 
inefective intervention may also be a best 
buy if it delivers suiciently strong equity 
outcomes. Thailand implemented a policy 
of peritoneal dialysis irst for patients with 
renal failure to ensure that people living 
in both urban and rural areas throughout 
the country could access the expensive, 
lifesaving treatment equally.23 24
Practical ways forward
NCD programme managers face challenges 
on several fronts, including information 
and political support. Keeping up with 
information in the health sector is not easy: 
75 trials and 11 systematic reviews are pub-
lished daily.25 Programme managers have to 
ind ways of identifying relevant informa-
tion. An expert hub, national or regional, 
could be used to gather, ilter, and review 
relevant information as well as to support 
evidence assessment and appraisal pro-
cesses.
Health technology assessment (HTA) is 
not just a collection of technical methods, 
such as cost-effectiveness analysis, but 
also a way of thinking. It must include 
the academic disciplines of medicine, 
epidemiology, economics, management, 
and ethics. Systematic thinking for 
evidence based and efficient decision 
making (SEED) is one tool for determining 
whether an intervention is likely to be 
worthwhile in a local context (fig 2). It 
considers both the cost effectiveness 
agenda and the wider context (see web 
supplement). Since transferring economic 
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Fig 1 | Cost efectiveness plane to show best buys and wasted buys. The broken line denotes 
the maximum amount the decision maker is willing to spend for additional health beneit. 
Interventions in quadrant A are clearly not cost efective compared with the current scenario 
and those in quadrant D are best buys. Decisions about interventions falling in quadrants B 
and C are less clear cut and will depend on the threshold set. The area of uncertainty indicates 
ranges of relatively small cost and beneit diferentials where uncertainty may be particularly 
troublesome
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evidence generated elsewhere to local 
settings is not straightforward,14 22 23 25 we 
suggest using a scrutiny sequence starting 
with an initial environmental scan of the 
economic evidence (high or low income, 
organisation of healthcare, local prices, 
etc), followed by a data transferability 
assessment (see web supplement).19 26 
An institutional hub of national or 
regional technical expertise could support 
NCD managers in obtaining a clearer 
understanding of the local implications 
for health technology and transferability 
assessment.
Deciding whether any prospective 
intervention for NCDs is likely to be a 
best buy is tricky. The criteria may not 
be agreed; the evidence on which an 
appraisal can be based is rarely complete, 
accurate, or locally applicable; and the 
processes through which a decision 
about a possible best buy is made may be 
secretive, dominated by speciic interest 
groups and incomprehensible to outsiders. 
Decision making needs to be credible to 
ensure policy acceptance and effective 
implementation. Any group likely to be 
afected by the decision needs to be able 
to examine the decision making process to 
discover whether the reasoning was sound, 
the value judgments were acceptable, and 
the evidence was appropriately identiied 
and interpreted.27 The public will also 
want to be satisfied that those involved 
in the process were competent, that they 
sought to promote the public interest, and 
that those who were there to represent the 
public were appointed in a fair way and 
could be held to account.
I n t e r v e n t i o n s  t a c k l i n g  s o c i a l 
determinants often require collaborations 
with other sectors, including government 
departments such as education, housing, 
and policing and the corporate sector. 
This may be a factor accounting for the 
underuse of best buys28 since nearly all 
systems of public administration are 
vertical and tend to make decisions in 
silos. Cross sectoral projects should be 
evaluated in the same way as all other 
uses of health sector funds.29 To be 
acceptable, the inancial contribution of 
the health sector to a cross sectoral project 
should yield suicient health beneits to 
make the project cost efective. Decisions 
ought to allow the full participation of 
sectoral partners. Systems characterised 
by short term planning and siloed 
budgets tend not to prioritise actions 
whose beneits are realised in the future 
and in sectors which did not initiate the 
original spend. Moreover, the structures 
of service delivery, whether, for example, 
an NCD unit is in or outside a ministry, 
could further inhibit the successful 
implementation of  interventions. 
High level commitment and support 
at national and international levels is 
needed to scale up and accelerate the 
implementation of cross sectoral policies 
and interdepartmental collaboration for 
prevention and control of NCDs.30
Interventions to prevent NCDs are 
often complex, constantly changing, 
and unique to each jurisdiction. There is 
Identify factors contributing
to high cost implementation
and identify mechanism or
measures to reduce cost.
If unsuccesful, think about
alternative options
Bring evidence to policy discussion or develop an evidence informed policy development
mechanism and capacity among stakeholders in using evidence to inform policy
Revise policy intervention to be
based on theoretical grounds
Explore generalisability and transferability of
evidence and, if needed, identify additional measures
that adjust for external or contextual factors.
If unsuccesful, think about alternative options
Design and conduct appropriate impact evaluation
to identify intervention effectiveness, etc
Best
Buys
32
41
5
Are there known
external or contextual
factors that contribute to
intervention’s effectiveness
that differ from study and
implementation settings?
If no
If no
If no
If noIf no Is there good
evidence on
intervention
effectiveness on the
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implementation plan?*
Is there political buy-in?
          Can this
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Fig 2 | SEED tool for determining whether an intervention is likely to be worthwhile in a local context. The tool has two sections: the inner 
circle aims to assist NCD programme managers in thinking critically about the intervention and the outer boxes provide recommendations for 
strengthening the evidence base. *Implementation=dosage, frequency. duration, coverage, etc, †Compared with the cost of implementing a 
similar programme in other settings or the costs in the economic evaluation studies used to decide to implement the intervention
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no single solution for all policy makers, 
but there are positive steps that can be 
taken to further their eforts. Whether an 
intervention for NCD prevention will be 
best, wasted, or contestable depends on 
the context. To understand the context is 
every bit as important as to understand the 
technologies of evaluation, and we have 
suggested some ways in which this might 
be done.
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